NCT01701986 - Gemcitabine Hydrochloride, Clofarabine, and Busulfan Before Donor Stem Cell Transplant in Treating Patients With Refractory B-Cell or T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 25, 2012

Primary Completion Date

June 5, 2024

Study Completion Date

June 5, 2024

Conditions

Hematopoietic Cell Transplantation RecipientRefractory B-Cell Non-Hodgkin LymphomaRefractory Hodgkin LymphomaRefractory T-Cell Non-Hodgkin Lymphoma

Interventions

PROCEDURE

Allogeneic Bone Marrow Transplantation

Undergo allogeneic BMT

PROCEDURE

Allogeneic Hematopoietic Stem Cell Transplantation

Undergo allogeneic BMT or PBSCT

BIOLOGICAL

Anti-Thymocyte Globulin

Given IV

DRUG

Busulfan

Given IV

DRUG

Clofarabine

Given IV

DRUG

Gemcitabine Hydrochloride

Given IV

DRUG

Mycophenolate Mofetil

Given IV then PO

PROCEDURE

Peripheral Blood Stem Cell Transplantation

Undergo allogeneic PBSCT

OTHER

Pharmacological Study

Correlative studies

BIOLOGICAL

Rituximab

Given IV

DRUG

Tacrolimus

Given IV then PO

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER